Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $11.87, but opened at $12.37. Corvus Pharmaceuticals shares last traded at $11.8020, with a volume of 159,690 shares changing hands.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $33.33.
Check Out Our Latest Stock Analysis on Corvus Pharmaceuticals
Corvus Pharmaceuticals Stock Performance
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, sell-side analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.79 EPS for the current fiscal year.
Institutional Investors Weigh In On Corvus Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter worth about $106,654,000. Commodore Capital LP purchased a new position in shares of Corvus Pharmaceuticals during the first quarter valued at $33,045,000. Perceptive Advisors LLC lifted its position in shares of Corvus Pharmaceuticals by 231.1% in the 1st quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock worth $33,538,000 after purchasing an additional 1,600,000 shares during the period. Bank of America Corp DE purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $11,322,000. Finally, DCF Advisers LLC bought a new position in Corvus Pharmaceuticals in the fourth quarter worth about $5,613,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the immune system to treat cancer and other serious diseases. The company’s research is centered on small-molecule and antibody-based therapies designed to influence immune-cell activity and improve the body’s ability to respond to disease.
Corvus’ lead investigational product is soquelitinib, also known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK).
Featured Articles
- Five stocks we like better than Corvus Pharmaceuticals
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
- Meta’s Muse Is Taking Aim at E-Commerce, But Amazon Isn’t Playing Along
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
